Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
BeOne Medicines
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MEI Pharma, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
Massachusetts General Hospital
Galapagos NV
AbbVie
Beth Israel Deaconess Medical Center
Masonic Cancer Center, University of Minnesota
BeOne Medicines
National Institutes of Health Clinical Center (CC)
University of Chicago
Regeneron Pharmaceuticals
University of Washington
The First Affiliated Hospital with Nanjing Medical University
Genmab
Genmab
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Fred Hutchinson Cancer Center
University of Ulm
Mayo Clinic
Fudan University
Medical College of Wisconsin
BeOne Medicines
Ascentage Pharma Group Inc.
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
Vironexis Biotherapeutics Inc.
International Extranodal Lymphoma Study Group (IELSG)
LTZ Therapeutics, Inc.
Eli Lilly and Company
Enterome
City of Hope Medical Center
BeOne Medicines
iOMEDICO AG
Eli Lilly and Company
AbbVie
AbbVie
International Extranodal Lymphoma Study Group (IELSG)
Novartis
Beijing Tongren Hospital